Your browser version may not work well with NCBI's Web applications. More information here...
1: Curr Opin Investig Drugs. 2008 Oct;9(10):1108-15.Links

Dexlansoprazole, a modified release formulation of an enantiomer of lansoprazole, for the treatment of reflux esophagitis.

Fock KM, Ang TL.

Changi General Hospital, Department of Medicine, Division of Gastroenterology, 2 Simei Street 3, 529889, Singapore. kwong_ming_fock@cgh.com.sg

Takeda Pharmaceutical Co Ltd is developing dexlansoprazole, an oral controlled-release formulation of an enantiomer of lansoprazole, for the treatment of reflux esophagitis. By January 2008, an NDA for gastric acid-related diseases had been filed with the FDA, and the drug was undergoing phase II trials in Japan for gastroesophageal reflux disease.

PMID: 18821474 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Dexlansoprazole (Kapidex® )

    Dexlansoprazole is used to treat heartburn in people who have gastroesophageal reflux disease (GERD; condition in which backward flow of acid from the stomach causes symptoms such as heartburn, burping, and sour taste). ...

  • Lansoprazole (Prevacid® , Prevacid® NapraPAC® , Prevacid® SoluTab® , ...)

    Lansoprazole is used to treat ulcers; gastroesophageal reflux disease (GERD), a condition in which backward flow of acid from the stomach causes heartburn and injury of the food pipe (esophagus); and conditions where the...

  • Source: AHFS Consumer Medication Information